Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series - Poll - MDSpire

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

  • By

  • Sandra Susanibar-Adaniya

  • Benjamin A. Derman

  • Adam D. Cohen

  • Dan T. Vogl

  • Shambavi Richard

  • Adriana Rossi

  • Matthew J. Frigualt

  • Andrew J. Yee

  • Binod Dhakal

  • Noffar Bar

  • April 28, 2026

  • 0 min

Share

Original Source(s)

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

  • by Sandra Susanibar-Adaniya, Benjamin A. Derman, Adam D. Cohen, Dan T. Vogl, Shambavi Richard, Adriana Rossi, Matthew J. Frigualt, Andrew J. Yee, Binod Dhakal, Noffar Bar

  • April 28, 2026

Related Content

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Comprehensive Evaluation of miR-15a-5p, miR-20a-5p, and miR-33b-3p Reveals EGR2-Related Biomarkers in Multiple Myeloma